Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENOGUARD renal protection study in Lutetium-177 PSMA therapy
ACTRN12624000695505Phase 2Recruiting
- Sponsor
- Fiona Stanley Hospital
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Synthamin 17, lutetium lu 177 vipivotide tetraxetan and lutetium Lu 177 PSMA I&T in prostate cancer (PCa) (3 arms), sponsored by Fiona Stanley Hospital. Started Jul 2024; status: recruiting.
02
Drugs
Synthamin 17lutetium lu 177 vipivotide tetraxetanlutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12624000695505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000695505.